Advanced Biomed Inc. Common Stock (ADVB)vsNatera Inc (NTRA)
ADVB
Advanced Biomed Inc. Common Stock
$2.64
-11.41%
HEALTHCARE · Cap: $6.58M
NTRA
Natera Inc
$436.00
+2.73%
HEALTHCARE · Cap: $61.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 2120768% more annual revenue ($2.71B vs $127,640). ADVB leads profitability with a 5231.0% profit margin vs -7.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).
ADVB
Avoid30
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 5231 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Revenue surging 37.7% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
0.0% earnings growth
Weak financial health signals
Trading at 34.4x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADVB
The strongest argument for ADVB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 5231.0% and operating margin at -3856.0%.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Market Cap, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : ADVB
The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ADVB profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
ADVB generates stronger free cash flow (-583,768), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NTRA scores higher overall (31/100 vs 30/100) and 37.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Advanced Biomed Inc. Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?